GleamWall
中文EN

CLYM Climb Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1768446 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY-37.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.3%
ROA-28.3%
ROIC (approx.)-31.1%
Asset turnover—

Leverage & solvency

Liabilities / assets3.6%
Debt / equity0.00x
Current ratio26.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$11.04M$9.71M$9.37M$13.74M$9.07M$6.58M$17.33M$5.96M
SG&A expense$5.85M$5.64M$5.84M$5.56M$5.82M$4.10M$5.69M$4.95M
Operating income-$16.89M-$15.36M-$15.21M-$19.30M-$14.89M-$10.68M-$23.02M-$10.91M
Income tax——————$0$0
Net income-$14.57M-$13.50M-$13.72M-$17.52M-$12.89M-$8.67M-$20.78M-$8.42M
EBITDA-$16.70M-$15.33M-$15.17M-$19.27M-$14.86M-$10.64M-$23.02M-$10.91M
EPS (basic)-0.18-0.18-0.20—-0.19-0.13-0.31—
EPS (diluted)-0.18-0.18-0.20—-0.19-0.13-0.31—
Weighted avg. shares (diluted)80.03M76.15M68.21M—68.00M67.59M67.46M—
Balance sheet
Cash & equivalents$39.73M$44.11M$8.36M$35.69M$25.80M$22.68M$29.02M$87.23M
Short-term investments$165.69M$139.02M$101.21M$65.39M$61.10M$62.02M$69.04M$63.69M
Current assets$210.15M$186.64M$113.40M$105.85M$90.96M$87.38M$100.28M$154.87M
PP&E, net$1.33M$695,000$250,000$288,000$318,000$314,000—$199,000
Total assets$236.56M$246.29M$152.37M$167.74M$182.30M$192.39M$200.74M$217.19M
Current liabilities$7.91M$5.93M$4.07M$6.98M$4.95M$6.21M$7.04M$4.93M
Total liabilities$8.51M$6.75M$4.29M$7.27M$5.30M$6.62M$7.36M$5.31M
Shareholders' equity$228.05M$239.55M$148.09M$160.47M$177.00M$185.76M$193.38M$211.88M
Shares outstanding57.73M57.44M47.77M47.77M68.18M67.76M67.58M67.26M
Cash flow statement
Operating cash flow-$12.00M-$10.55M-$14.38M-$15.63M-$12.14M-$11.15M-$15.43M-$5.52M
Capital expenditure$820,000——$0$109,000——$0
Free cash flow-$12.82M——-$15.63M-$12.25M——-$5.52M
Investing cash flow$6.40M-$57.26M-$12.96M$25.54M$15.26M$4.79M-$42.75M-$53.41M
Financing cash flow$1.22M$103.70M$5,000-$21,000$0$0$0$41,000
Depreciation & amortization$195,000$33,000$38,000$30,000$29,000$38,000$0$0
Stock-based compensation$2.04M$1.48M$1.60M$1.04M$3.98M$1.01M$2.02M$1.66M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.